RN3161 (LY3841136) Phase 1/2a study evaluates safety, PK/PD, and body weight effects.
Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity
Abstract
A Phase 1/2a study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and body weight effects of RN3161 (LY3841136) as monotherapy and combined with tirzepatide.
TitrateLab articles covering Tirzepatide
Written by TitrateLab, separately from the study summarized above.
